Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development

Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity

(2013) Levente Szalardy et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

In vitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers

(2012) Emma Bishop et al.   BMC Cardiovascular Disorders

Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis

(2012) Sakhina Begum-Haque et al.   JOURNAL OF NEUROIMMUNOLOGY

Disease Biomarkers in Multiple Sclerosis

(2012) Violaine K. Harris et al.   Molecular Diagnosis & Therapy

Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

(2012) Clara de Andrés et al.   PLoS One

Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis

(2012) Lars Börnsen et al.   PLoS One

Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals

(2011) Ewa Stępień et al.   CLINICAL BIOCHEMISTRY

Osteopontin in Cardiovascular Disease

(2010) Alfonso H. Waller et al.   Cardiology in Review

Osteopontin expression and relation to disease severity in human asthma

(2010) K. Samitas et al.   EUROPEAN RESPIRATORY JOURNAL

Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers

(2010) Mario HJ Vogt et al.   Multiple Sclerosis Journal

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

(2010) Lars Börnsen et al.   Multiple Sclerosis Journal

Serum Osteopontin as a Predictive Marker of Responsiveness to Methotrexate in Juvenile Idiopathic Arthritis

(2009) L. MASI et al.   JOURNAL OF RHEUMATOLOGY

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study

(2009) S.A. Gauthier et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells

(2009) P. Kivisakk et al.   NEUROLOGY

Increased Osteopontin Levels in the Cerebrospinal Fluid of Patients With Multiple Sclerosis

(2008) Manjit Braitch et al.   ARCHIVES OF NEUROLOGY

Specificity and Correlation With Disease Activity of Cerebrospinal Fluid Osteopontin Levels in Patients With Multiple Sclerosis

(2008) Soheli A. Chowdhury et al.   ARCHIVES OF NEUROLOGY

Induction of systemic TNFα in Natalizumab-treated multiple sclerosis

(2008) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis

(2008) Yi-Ju Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design

(2008) Margaret S. Pepe et al.   JNCI-Journal of the National Cancer Institute

Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate

(2008) H. P. Sennels et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY